Abstract
Background: Posttraumatic stress disorder (PTSD) is accompanied by disrupted cortical neuroanatomy. We investigated alteration in covariance of structural networks associated with PTSD in regions that demonstrate the case-control differences in cortical thickness (CT) and surface area (SA). Methods: Neuroimaging and clinical data were aggregated from 29 research sites in >1300 PTSD cases and >2000 trauma-exposed control subjects (ages 6.2–85.2 years) by the ENIGMA-PGC (Enhancing Neuro Imaging Genetics through Meta Analysis–Psychiatric Genomics Consortium) PTSD working group. Cortical regions in the network were rank ordered by the effect size of PTSD-related cortical differences in CT and SA. The top-n (n = 2–148) regions with the largest effect size for PTSD > non-PTSD formed hypertrophic networks, the largest effect size for PTSD < non-PTSD formed atrophic networks, and the smallest effect size of between-group differences formed stable networks. The mean structural covariance (SC) of a given n-region network was the average of all positive pairwise correlations and was compared with the mean SC of 5000 randomly generated n-region networks. Results: Patients with PTSD, relative to non-PTSD control subjects, exhibited lower mean SC in CT-based and SA-based atrophic networks. Comorbid depression, sex, and age modulated covariance differences of PTSD-related structural networks. Conclusions: Covariance of structural networks based on CT and cortical SA are affected by PTSD and further modulated by comorbid depression, sex, and age. The SC networks that are perturbed in PTSD comport with converging evidence from resting-state functional connectivity networks and networks affected by inflammatory processes and stress hormones in PTSD.
Original language | English |
---|---|
Pages (from-to) | 935-948 |
Number of pages | 14 |
Journal | Biological Psychiatry: Cognitive Neuroscience and Neuroimaging |
Volume | 7 |
Issue number | 9 |
Early online date | 2022 |
DOIs | |
Publication status | Published - Sept 2022 |
Keywords
- Brain network
- Cortical thickness
- Depression
- PTSD
- Structural covariance
- Surface area
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, Vol. 7, No. 9, 09.2022, p. 935-948.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Remodeling of the Cortical Structural Connectome in Posttraumatic Stress Disorder
T2 - Results From the ENIGMA-PGC Posttraumatic Stress Disorder Consortium
AU - Sun, Delin
AU - Rakesh, Gopalkumar
AU - Clarke-Rubright, Emily K.
AU - Haswell, Courtney C.
AU - Logue, Mark W.
AU - O'Leary, Erin N.
AU - Cotton, Andrew S.
AU - Xie, Hong
AU - Dennis, Emily L.
AU - Jahanshad, Neda
AU - Salminen, Lauren E.
AU - Thomopoulos, Sophia I.
AU - Rashid, Faisal M.
AU - Ching, Christopher R. K.
AU - Koch, Saskia B. J.
AU - Frijling, Jessie L.
AU - Nawijn, Laura
AU - van Zuiden, Mirjam
AU - Zhu, Xi
AU - Suarez-Jimenez, Benjamin
AU - Sierk, Anika
AU - Walter, Henrik
AU - Manthey, Antje
AU - Stevens, Jennifer S.
AU - Fani, Negar
AU - van Rooij, Sanne J. H.
AU - Stein, Murray B.
AU - Bomyea, Jessica
AU - Koerte, Inga
AU - Choi, Kyle
AU - van der Werff, Steven J. A.
AU - Vermeiren, Robert R. J. M.
AU - Herzog, Julia I.
AU - Lebois, Lauren A. M.
AU - Baker, Justin T.
AU - Ressler, Kerry J.
AU - Olson, Elizabeth A.
AU - Straube, Thomas
AU - Korgaonkar, Mayuresh S.
AU - Andrew, Elpiniki
AU - Zhu, Ye
AU - Li, Gen
AU - Ipser, Jonathan
AU - Hudson, Anna R.
AU - Peverill, Matthew
AU - Sambrook, Kelly
AU - Gordon, Evan
AU - Baugh, Lee A.
AU - Forster, Gina
AU - Simons, Raluca M.
AU - Simons, Jeffrey S.
AU - Magnotta, Vincent A.
AU - Maron-Katz, Adi
AU - du Plessis, Stefan
AU - Disner, Seth G.
AU - Davenport, Nicholas D.
AU - Grupe, Dan
AU - Nitschke, Jack B.
AU - deRoon-Cassini, Terri A.
AU - Fitzgerald, Jacklynn
AU - Krystal, John H.
AU - Levy, Ifat
AU - Olff, Miranda
AU - Veltman, Dick J.
AU - Wang, Li
AU - Neria, Yuval
AU - de Bellis, Michael D.
AU - Jovanovic, Tanja
AU - Daniels, Judith K.
AU - Shenton, Martha E.
AU - van de Wee, Nic J. A.
AU - Schmahl, Christian
AU - Kaufman, Milissa L.
AU - Rosso, Isabelle M.
AU - Sponheim, Scott R.
AU - Hofmann, David Bernd
AU - Bryant, Richard A.
AU - Fercho, Kelene A.
AU - Stein, Dan J.
AU - Mueller, Sven C.
AU - Phan, K. Luan
AU - McLaughlin, Katie A.
AU - Davidson, Richard J.
AU - Larson, Christine
AU - May, Geoffrey
AU - Nelson, Steven M.
AU - Abdallah, Chadi G.
AU - Gomaa, Hassaan
AU - Etkin, Amit
AU - Seedat, Soraya
AU - Harpaz-Rotem, Ilan
AU - Liberzon, Israel
AU - Wang, Xin
AU - Thompson, Paul M.
AU - Morey, Rajendra A.
AU - ENIGMA Consortium PGC-PTSD
N1 - Funding Information: This study was funded by the Department of Defense (Grant Nos. W81XWH-10-1-0925 [to GF] , W81XWH-12-2-0012 [to PMT] , and W81XWH-08-2-0159 and W81XWH08-2-0159 [to MBS]); Center for Brain and Behavior Research Pilot Grant; South Dakota Governor’s Research Center Grant (to LAB); Veterans Affairs (VA) Career Development Award (Grant No. CX001600 [to JB] ); National Health and Medical Research Council (Grant No. 1073041 [to RAB] ); VISN6 MIRECC (to RAM); German Research Foundation (Grant Nos. DA 1222/4-1 and WA 1539/8-2 [to JKD]); VA Rehabilitation Research and Development (RR&D) (Grant Nos. 1IK2RX000709 , 1K1RX002325, and 1K2RX002922 [to SGD] , and I01RX000622 [to SRS] ); VA Clinical Science Research and Development (Grant No. 1IK2CX001680 [to EG] ); Veterans Affairs Merit Review Program (10/01/08 – 09/30/13); VISN17 Center of Excellence pilot funding; Department of Veterans Affairs via support for the National Center for PTSD ; VA Biomedical Laboratory Research and Development Grant No. I01BX003477 (to MWL); National Institute of Mental Health (NIMH) (Grant Nos. R01-MH043454 and T32-MH018931 [to RJD]; K24MH71434 , R01 MH63407 , and R01 MH61744 [to MDDB]; R01MH105535 [to IH-R]; 1R21MH102634 and 1R21MH102634 [to ILe]; R01MH113574 [to ILi]; R01-MH103291 [to KAM]; K23MH112873 [to EAO]; L30 MH114379 [to LES]; K01 MH118428 [to BS-J]; R01MH111671 [to RAM]; R01MH117601 [to NJ]; MH101380 [to NF]; K01-MH092526 [to KAM]; F32 MH101976 [to JSSt]; MH098212 [to TJ]; MH071537 and R21MH112956 [to KJR]; R01MH105355 [to YN]; F32MH109274 [to LAML]; 1R01MH110483 and 1R21 MH098198 [to XW]; R01MH105355-01A [to YN]; R01 MH106574 [to CL]); National Institute on Alcohol Abuse and Alcoholism Grant Nos. 5U01AA021681-08, DA028773, and R01 AA12479 (to MDDB); National Institute of Neurological Disorders and Stroke Grant No. K99NS096116 (to ELD); ZonMw , the Netherlands Organisation for Health Research and Development grant (Grant No. 40-00812-98-10041 [to MO]); Academic Medical Center Research Council (Grant No. 110614 [to MO]); German Federal Ministry of Education and Research (BMBF) (RELEASE Grant No. 01KR1303A [to Martin Bohus]); German Research Foundation (Grant No. SFB/TRR 58: C06, C07 [to DBH]); National Institute of Aging Grant Nos. R01AG059874 and Michael J. Fox Foundation 14848 (to NJAvdW); National Center for Research Resources (Grant Nos. M01RR00039 [to KJR] ); National Center for Advancing Translational Sciences (NCATS) (Grant No. UL1TR000454 [to JSSt] ), Eunice Kennedy Shriver National Institute of Child Health and Human Development (Grant Nos. HD071982 and HD085850 [to JSSt] ); Anonymous Women’s Health Fund, Barlow Family Fund , Kasparian Fund , O'Keefe Family Foundation , Trauma Scholars Fund , and Frazier Foundation Grant for Mood and Anxiety Research McLean Hospital (to MLK); Child Health Research Award, Charles H. Hood Foundation and Young Investigator Grant, Brain and Behavior Foundation (to KAM); National Institute on Alcohol Abuse and Alcoholism via its support for (P50) Center for the Translational Neuroscience of Alcohol; NCATS via its support of (Clinical and Translational Science Awards) Yale Center for Clinical Investigation; BOF 2-4 year project (Grant No. 01J05415 [to SCM]); Dana Foundation (to JBN); the University of Wisconsin Institute for Clinical and Translational Research; a National Science Foundation Graduate Research Fellowship (to DG); core grant to the Waisman Center from the National Institute of Child Health and Human Development (Grant No. P30-HD003352 ); South African Medical Research Council; South African Medical Research Council “SHARED ROOTS” Flagship Project; Grant MRC-RFA-FSP-01-2013 /SHARED ROOTS; South African Research Chair in Posttraumatic stress disorder (PTSD) from the Department of Science and Technology and the National Research Foundation ; MRC Unit on Anxiety & Stress Disorders and Bill and Melinda Gates Foundation Grant No. OPP 1017641 (to DJS); Congressionally Directed Medical Research Programs Grant No. W81XWH-08–2–0038 (to SRS); and NARSAD Young Investigator. ENIGMA was also supported in part by NIH U54 EB020403 from the Big Data to Knowledge (BD2K) program and NIH grants (Grant Nos. R56AG058854 , R01MH116147 , R01MH111671 , and P41 EB015922 [to PMT] ). Funding Information: CGA has served as a consultant, speaker and/or on advisory boards for FSV7, Lundbeck, Psilocybin Labs, Genentech, and Janssen; served as editor of Chronic Stress for Sage Publications, Inc; and filed a patent for using mTOR inhibitors to augment the effects of antidepressants (filed on August 20, 2018). RJD is the founder and president of, and serves on the board of directors for, the nonprofit organization Healthy Minds Innovations, Inc. NJ received partial research support from Biogen, Inc for research unrelated to the content of this manuscript. JHK is a consultant for AbbVie, Amgen, Astellas Pharma Global Development, AstraZeneca Pharmaceuticals, Biomedisyn Corporation, Bristol-Myers Squibb, Eli Lilly and Company, Euthymics Bioscience, Neurovance, FORUM Pharmaceuticals, Janssen Research & Development, Lundbeck Research USA, Novartis Pharma AG, Otsuka America Pharmaceutical, Sage Therapeutics, Sunovion Pharmaceuticals, and Takeda Industries; is on the scientific advisory board for Lohocla Research Corporation, Mnemosyne Pharmaceuticals, Naurex, and Pfizer; is a stockholder in Biohaven Pharmaceuticals; holds stock options in Mnemosyne Pharmaceuticals; holds patents for Dopamine and Noradrenergic Reuptake Inhibitors in Treatment of Schizophrenia, US Patent No. 5,447,948 (issued September 5, 1995), and Glutamate Modulating Agents in the Treatment of Mental Disorders, US Patent No. 8,778,979 (issued July 15, 2014); and filed a patent for Intranasal Administration of Ketamine to Treat Depression (U.S. Application No. 14/197,767 [filed on March 5, 2014]), US application or Patent Cooperation Treaty international application No. 14/306,382 (filed on June 17, 2014), and a patent for using mTOR inhibitors to augment the effects of antidepressants (filed on August 20, 2018). CS is consultant for Boehringer Ingelheim International GmbH. DJS has received research grants and/or consultancy honoraria from Lundbeck and Sun. PMT received partial research support from Biogen for research unrelated to the topic of this manuscript. All other authors report no biomedical financial interests or potential conflicts of interest. Funding Information: This study was funded by the Department of Defense (Grant Nos. W81XWH-10-1-0925 [to GF], W81XWH-12-2-0012 [to PMT], and W81XWH-08-2-0159 and W81XWH08-2-0159 [to MBS]); Center for Brain and Behavior Research Pilot Grant; South Dakota Governor's Research Center Grant (to LAB); Veterans Affairs (VA) Career Development Award (Grant No. CX001600 [to JB]); National Health and Medical Research Council (Grant No. 1073041 [to RAB]); VISN6 MIRECC (to RAM); German Research Foundation (Grant Nos. DA 1222/4-1 and WA 1539/8-2 [to JKD]); VA Rehabilitation Research and Development (RR&D) (Grant Nos. 1IK2RX000709, 1K1RX002325, and 1K2RX002922 [to SGD], and I01RX000622 [to SRS]); VA Clinical Science Research and Development (Grant No. 1IK2CX001680 [to EG]); Veterans Affairs Merit Review Program (10/01/08 – 09/30/13); VISN17 Center of Excellence pilot funding; Department of Veterans Affairs via support for the National Center for PTSD; VA Biomedical Laboratory Research and Development Grant No. I01BX003477 (to MWL); National Institute of Mental Health (NIMH) (Grant Nos. R01-MH043454 and T32-MH018931 [to RJD]; K24MH71434, R01 MH63407, and R01 MH61744 [to MDDB]; R01MH105535 [to IH-R]; 1R21MH102634 and 1R21MH102634 [to ILe]; R01MH113574 [to ILi]; R01-MH103291 [to KAM]; K23MH112873 [to EAO]; L30 MH114379 [to LES]; K01 MH118428 [to BS-J]; R01MH111671 [to RAM]; R01MH117601 [to NJ]; MH101380 [to NF]; K01-MH092526 [to KAM]; F32 MH101976 [to JSSt]; MH098212 [to TJ]; MH071537 and R21MH112956 [to KJR]; R01MH105355 [to YN]; F32MH109274 [to LAML]; 1R01MH110483 and 1R21 MH098198 [to XW]; R01MH105355-01A [to YN]; R01 MH106574 [to CL]); National Institute on Alcohol Abuse and Alcoholism Grant Nos. 5U01AA021681-08, DA028773, and R01 AA12479 (to MDDB); National Institute of Neurological Disorders and Stroke Grant No. K99NS096116 (to ELD); ZonMw, the Netherlands Organisation for Health Research and Development grant (Grant No. 40-00812-98-10041 [to MO]); Academic Medical Center Research Council (Grant No. 110614 [to MO]); German Federal Ministry of Education and Research (BMBF) (RELEASE Grant No. 01KR1303A [to Martin Bohus]); German Research Foundation (Grant No. SFB/TRR 58: C06, C07 [to DBH]); National Institute of Aging Grant Nos. R01AG059874 and Michael J. Fox Foundation 14848 (to NJAvdW); National Center for Research Resources (Grant Nos. M01RR00039 [to KJR]); National Center for Advancing Translational Sciences (NCATS) (Grant No. UL1TR000454 [to JSSt]), Eunice Kennedy Shriver National Institute of Child Health and Human Development (Grant Nos. HD071982 and HD085850 [to JSSt]); Anonymous Women's Health Fund, Barlow Family Fund, Kasparian Fund, O'Keefe Family Foundation, Trauma Scholars Fund, and Frazier Foundation Grant for Mood and Anxiety Research McLean Hospital (to MLK); Child Health Research Award, Charles H. Hood Foundation and Young Investigator Grant, Brain and Behavior Foundation (to KAM); National Institute on Alcohol Abuse and Alcoholismvia its support for (P50) Center for the Translational Neuroscience of Alcohol; NCATS via its support of (Clinical and Translational Science Awards) Yale Center for Clinical Investigation; BOF 2-4 year project (Grant No. 01J05415 [to SCM]); Dana Foundation (to JBN); the University of Wisconsin Institute for Clinical and Translational Research; a National Science Foundation Graduate Research Fellowship (to DG); core grant to the Waisman Center from the National Institute of Child Health and Human Development (Grant No. P30-HD003352); South African Medical Research Council; South African Medical Research Council “SHARED ROOTS” Flagship Project; Grant MRC-RFA-FSP-01-2013/SHARED ROOTS; South African Research Chair in Posttraumatic stress disorder (PTSD) from the Department of Science and Technology and the National Research Foundation; MRC Unit on Anxiety & Stress Disorders and Bill and Melinda Gates Foundation Grant No. OPP 1017641 (to DJS); Congressionally Directed Medical Research Programs Grant No. W81XWH-08–2–0038 (to SRS); and NARSAD Young Investigator. ENIGMA was also supported in part by NIH U54 EB020403 from the Big Data to Knowledge (BD2K) program and NIH grants (Grant Nos. R56AG058854, R01MH116147, R01MH111671, and P41 EB015922 [to PMT]). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs, the U.S. Government, or any other funding sources listed here. CGA has served as a consultant, speaker and/or on advisory boards for FSV7, Lundbeck, Psilocybin Labs, Genentech, and Janssen; served as editor of Chronic Stress for Sage Publications, Inc; and filed a patent for using mTOR inhibitors to augment the effects of antidepressants (filed on August 20, 2018). RJD is the founder and president of, and serves on the board of directors for, the nonprofit organization Healthy Minds Innovations, Inc. NJ received partial research support from Biogen, Inc for research unrelated to the content of this manuscript. JHK is a consultant for AbbVie, Amgen, Astellas Pharma Global Development, AstraZeneca Pharmaceuticals, Biomedisyn Corporation, Bristol-Myers Squibb, Eli Lilly and Company, Euthymics Bioscience, Neurovance, FORUM Pharmaceuticals, Janssen Research & Development, Lundbeck Research USA, Novartis Pharma AG, Otsuka America Pharmaceutical, Sage Therapeutics, Sunovion Pharmaceuticals, and Takeda Industries; is on the scientific advisory board for Lohocla Research Corporation, Mnemosyne Pharmaceuticals, Naurex, and Pfizer; is a stockholder in Biohaven Pharmaceuticals; holds stock options in Mnemosyne Pharmaceuticals; holds patents for Dopamine and Noradrenergic Reuptake Inhibitors in Treatment of Schizophrenia, US Patent No. 5,447,948 (issued September 5, 1995), and Glutamate Modulating Agents in the Treatment of Mental Disorders, US Patent No. 8,778,979 (issued July 15, 2014); and filed a patent for Intranasal Administration of Ketamine to Treat Depression (U.S. Application No. 14/197,767 [filed on March 5, 2014]), US application or Patent Cooperation Treaty international application No. 14/306,382 (filed on June 17, 2014), and a patent for using mTOR inhibitors to augment the effects of antidepressants (filed on August 20, 2018). CS is consultant for Boehringer Ingelheim International GmbH. DJS has received research grants and/or consultancy honoraria from Lundbeck and Sun. PMT received partial research support from Biogen for research unrelated to the topic of this manuscript. All other authors report no biomedical financial interests or potential conflicts of interest. Publisher Copyright: © 2022 Society of Biological Psychiatry
PY - 2022/9
Y1 - 2022/9
N2 - Background: Posttraumatic stress disorder (PTSD) is accompanied by disrupted cortical neuroanatomy. We investigated alteration in covariance of structural networks associated with PTSD in regions that demonstrate the case-control differences in cortical thickness (CT) and surface area (SA). Methods: Neuroimaging and clinical data were aggregated from 29 research sites in >1300 PTSD cases and >2000 trauma-exposed control subjects (ages 6.2–85.2 years) by the ENIGMA-PGC (Enhancing Neuro Imaging Genetics through Meta Analysis–Psychiatric Genomics Consortium) PTSD working group. Cortical regions in the network were rank ordered by the effect size of PTSD-related cortical differences in CT and SA. The top-n (n = 2–148) regions with the largest effect size for PTSD > non-PTSD formed hypertrophic networks, the largest effect size for PTSD < non-PTSD formed atrophic networks, and the smallest effect size of between-group differences formed stable networks. The mean structural covariance (SC) of a given n-region network was the average of all positive pairwise correlations and was compared with the mean SC of 5000 randomly generated n-region networks. Results: Patients with PTSD, relative to non-PTSD control subjects, exhibited lower mean SC in CT-based and SA-based atrophic networks. Comorbid depression, sex, and age modulated covariance differences of PTSD-related structural networks. Conclusions: Covariance of structural networks based on CT and cortical SA are affected by PTSD and further modulated by comorbid depression, sex, and age. The SC networks that are perturbed in PTSD comport with converging evidence from resting-state functional connectivity networks and networks affected by inflammatory processes and stress hormones in PTSD.
AB - Background: Posttraumatic stress disorder (PTSD) is accompanied by disrupted cortical neuroanatomy. We investigated alteration in covariance of structural networks associated with PTSD in regions that demonstrate the case-control differences in cortical thickness (CT) and surface area (SA). Methods: Neuroimaging and clinical data were aggregated from 29 research sites in >1300 PTSD cases and >2000 trauma-exposed control subjects (ages 6.2–85.2 years) by the ENIGMA-PGC (Enhancing Neuro Imaging Genetics through Meta Analysis–Psychiatric Genomics Consortium) PTSD working group. Cortical regions in the network were rank ordered by the effect size of PTSD-related cortical differences in CT and SA. The top-n (n = 2–148) regions with the largest effect size for PTSD > non-PTSD formed hypertrophic networks, the largest effect size for PTSD < non-PTSD formed atrophic networks, and the smallest effect size of between-group differences formed stable networks. The mean structural covariance (SC) of a given n-region network was the average of all positive pairwise correlations and was compared with the mean SC of 5000 randomly generated n-region networks. Results: Patients with PTSD, relative to non-PTSD control subjects, exhibited lower mean SC in CT-based and SA-based atrophic networks. Comorbid depression, sex, and age modulated covariance differences of PTSD-related structural networks. Conclusions: Covariance of structural networks based on CT and cortical SA are affected by PTSD and further modulated by comorbid depression, sex, and age. The SC networks that are perturbed in PTSD comport with converging evidence from resting-state functional connectivity networks and networks affected by inflammatory processes and stress hormones in PTSD.
KW - Brain network
KW - Cortical thickness
KW - Depression
KW - PTSD
KW - Structural covariance
KW - Surface area
UR - http://www.scopus.com/inward/record.url?scp=85130467346&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.bpsc.2022.02.008
DO - https://doi.org/10.1016/j.bpsc.2022.02.008
M3 - Article
C2 - 35307575
SN - 2451-9022
VL - 7
SP - 935
EP - 948
JO - Biological psychiatry. Cognitive neuroscience and neuroimaging
JF - Biological psychiatry. Cognitive neuroscience and neuroimaging
IS - 9
ER -